Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

This trial is testing a combination of drugs — cabozantinib (a targeted therapy), durvalumab (an immunotherapy), and possibly tremelimumab (another immunotherapy) — in patients with advanced stomach, esophageal, colorectal, or liver cancer. **You may be eligible if...** - You are 18 years or older in reasonably good health (ECOG score 0–1) - You have been diagnosed with advanced or locally unresectable gastric, esophageal, colorectal, or liver cancer - Your cancer can be measured on scans - You are willing to have a tumor biopsy before treatment starts - For stomach and esophageal cancers: you have already tried at least one standard therapy and it stopped working - For colorectal cancer: you have tried at least two prior standard therapies - For liver cancer: you have tried at least one prior therapy (depending on the study group) **You may NOT be eligible if...** - Your cancer has not been treated with the required number of prior therapies - You are unwilling or unable to have a tumor biopsy - Your overall health is too poor for this treatment combination Talk to your doctor to see if this trial is right for you.